← All trials
NCT00553631
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2008
- Primary completion
- May 1, 2009
- Completion date
- Jun 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ShireLead sponsor
- Hebrew UniversityOverall official - principal investigator
- Sociedad Espanola de Socorros MutuosOverall official - principal investigator
- La Rabta HospitalOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- ShireStudy director
- All India Institute of Medical SciencesOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- Malabar Institute of Medical SciencesOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Your Health Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.